|Application ||WB, IF, E|
|Other Accession||NP_002154, 4504567|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||47219 Da|
|Application Notes||IRF8 antibody can be used for detection of IRF8 by Western blot at 1 µg/mL. For immunofluorescence start at 10 µg/mL.|
|Other Names||IRF8 Antibody: Interferon regulatory factor 3, IRF-3, interferon regulatory factor 3|
|Reconstitution & Storage||IRF8 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||IRF8 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Key transcriptional regulator of type I interferon (IFN)-dependent immune responses which plays a critical role in the innate immune response against DNA and RNA viruses. Regulates the transcription of type I IFN genes (IFN-alpha and IFN-beta) and IFN-stimulated genes (ISG) by binding to an interferon-stimulated response element (ISRE) in their promoters. Acts as a more potent activator of the IFN-beta (IFNB) gene than the IFN-alpha (IFNA) gene and plays a critical role in both the early and late phases of the IFNA/B gene induction. Found in an inactive form in the cytoplasm of uninfected cells and following viral infection, double-stranded RNA (dsRNA), or toll-like receptor (TLR) signaling, is phosphorylated by IKBKE and TBK1 kinases. This induces a conformational change, leading to its dimerization and nuclear localization and association with CREB binding protein (CREBBP) to form dsRNA-activated factor 1 (DRAF1), a complex which activates the transcription of the type I IFN and ISG genes. Can activate distinct gene expression programs in macrophages and can induce significant apoptosis in primary macrophages.|
|Cellular Location||Cytoplasm. Nucleus. Note=Shuttles between cytoplasmic and nuclear compartments, with export being the prevailing effect. When activated, IRF3 interaction with CREBBP prevents its export to the cytoplasm|
|Tissue Location||Expressed constitutively in a variety of tissues|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
IRF8 Antibody: Interferons (IFN)s are involved in a multitude of immune interactions during viral infections and play a major role in both the induction and regulation of innate and adaptive antiviral mechanisms. During infection, host-virus interactions signal downstream molecules such as transcription factors such as IFN regulatory factor-3 (IRF3) which can act to stimulate transcription of IFN-alpha/beta genes. Unlike IRF3, IRF8 appears to act as a negative regulator of IFN-induced genes in most cases, but IRF8 mediates activation of NF-κB by the toll-like receptor 9 (TLR9) after stimulation by unmethylated CpG DNA in dendritic cells. Finally, it has been shown that IRF8 decreases bcl-2 expression and thus may play a role in chronic myelogenous leukemia.
Malmgaard L. Induction and regulation of IFNs during viral infections. J. Interferon & Cyto. Res. 2004; 24:439-54
Weisz A, Marx P, Sharf R, et al. The human interferon consensus sequence binding protein (H-ICSBP) is a negative regulator of enhancer elements common to interferon inducible genes. J. Biol. Chem. 1992; 267:25589-96.
Nelson N, Marks MS, Driggers PH, et al. Interferon consensus sequence-binding protein, a member of the interferon regulatory factor family, suppresses interferon-induced gene transcription. Mol. Cell. Biol. 1993; 13:588-99.
Tsujimura H, Tamura T, Kong HJ, et al. Toll-like receptor 9 signaling activates NF-κB through IFN regulatory factor-8/IFN consensus sequence binding protein in dendritic cells. J. Immunol. 2004; 172:6820-7.
If you have any additional inquiries please email technical services at email@example.com.